FRI092 Rationale And Design Of The Balance Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Olezarsen In Patients With Familial Chylomicronemia Syndrome

Disclosure: V. Alexander: Employee; Self; Ionis Pharmaceuticals Inc. E. Karwatowska-Prokopczuk: Employee; Self; Ionis Pharmaceuticals Inc. E.S. Stroes: Other; Self; Akcea Therapeutics, Ionis Pharmaceuticals Inc., Amgen Inc, Novo Nordisk, AstraZeneca, Esperion. C. Ballantyne: Speaker; Self; Ionis Pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexander, Veronica, Karwatowska-Prokopczuk, Ewa, Stroes, Erik S G, Ballantyne, Christie, Ginsberg, Henry N, Xia, Shuting, Witztum, Joseph, Tsimikas, Sam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Cardiovascular Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555401/
http://dx.doi.org/10.1210/jendso/bvad114.606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555401/
http://dx.doi.org/10.1210/jendso/bvad114.606

Ejemplares similares